

-2-

106. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody comprises a non-human variable region or a TNF-binding portion thereof and a human constant region.

107. The method of Claim 106 wherein the non-human variable region is of murine origin.

108. The method of Claim 106 wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.

109. The method of Claim 106 wherein said anti-TNF chimeric antibody does not bind to one or more epitopes included in amino acids 11-13, 37-42, 4957 or 155-157 of SEQ ID NO.: 1 of hTNF.

110. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody competitively inhibits binding of TNF to a monoclonal antibody selected from the group consisting of A2 or cA2.

111. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of an anti-TNF chimeric antibody, wherein said anti-TNF chimeric antibody


-3-

binds to amino acids between 87-108 or both 59-80 and 87-108 of SEQ ID NO.:1 of hTNF.

112. A method of treating Crohn's disease in a human comprising administering to the human an effective TNF-inhibiting amount of chimeric anti-TNF antibody cA2.

Claims 106-112 are pending. Entry of the Preliminary Amendment prior to examination of the application is respectfully requested and pursuant to the telephone conversation between Examiner Nisbet and the undersigned on December 1, 1995. This amendment is made to reduce issues on examination expedite prosecution. The application is now in condition for allowance. If the Examiner feels that a telephonic interview would facilitate examination, he is encouraged to telephone the undersigned at (617)861-6240.

Respectfully submitted,



Carolyn S. Elmore

Registration No. 37,567

Patent Agent

(617) 861-6240

Lexington, MA 02173

Dated: 12/5/95